WL2

Up to 55% of menopausal women experience weight gain and obesity following the menopause.

The weight gain is thought to increase the risk of type 2 diabetes (19.4%) and cardiovascular disease from 4% to 38% after menopause. Post-menopausal weight gain is associated with metabolic changes and fat redistribution from the hips to the abdomen. Although MHT is useful at reducing the risk of weight gain and type 2 diabetes, its long-term use is associated with increased risk for other diseases and therefore is not recommended. WL2 is an estrogen receptor α-tissue selective modulator resulting in weight loss and reversal of fat redistribution without the increased risk of breast and uterine cancer as well as clotting events.